CTLA4 and neoplasm: The expression of PD-L1 on tumor cells contributes to the prediction of clinical efficacy of ICI in some tumor types, such as non-small cell lung cancer, which take advantage of the crucial roles played by the PD-L1/PD-1 and CTLA4/CD80/CD86 axes in the evasion of immune surveillance.